Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.

Date publication

mars 2020

Journal

Gut

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas , Dr DAVIDSON Irwin , Pr PESSAUX Patrick , Dr MUKHERJI Atish , Dr CROUCHET Emilie

Tous les auteurs :
Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C, Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC, Baumert TF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32217639

Résumé

Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention.

Mots clés

chemoprevention, gene expression, hepatitis C, hepatocellular carcinoma, non-alcoholic steatohepatitis

Référence

Gut. 2020 Mar 26;: